Low dose chemotherapy in combination with insulin for the treatment of advanced metastatic tumors. Preliminary experience

Journal of B.U.ON.

Volumn 14, Issue 4, 2009, Pages 711-715

  Damyanov, Christo ^a   Radoslavova, M ^a   Gavrilov, V ^a   Stoeva, D ^a  

^a Medical Center of Integrative Medicine   (Bulgaria)

Author keywords

Insulin enhanced antitumor response; Insulin potential therapy

Indexed keywords

CA 15-3 ANTIGEN; CARBOPLATIN; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; CYPROTERONE ACETATE; DEXAMETHASONE; DOCETAXEL; DOXYCYCLINE; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; GOSERELIN; INSULIN; KETOPROFEN; MELOXICAM; METHOTREXATE; NAVELBINE; SILYMARIN; ZOLEDRONIC ACID;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; ARTICLE; BONE METASTASIS; BREAST BIOPSY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER THERAPY; CASE REPORT; CLINICAL PRACTICE; FEMALE; HUMAN; INSULIN POTENTIAL THERAPY; INSULIN TREATMENT; INTRADUCTAL CARCINOMA; KARNOFSKY PERFORMANCE STATUS; LABORATORY TEST; LIVER METASTASIS; LOW DRUG DOSE; LUNG METASTASIS; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAINTENANCE THERAPY; MALE; MULTIPLE CYCLE TREATMENT; PROSTATE CARCINOMA; SEGMENTAL MASTECTOMY; SOMNOLENCE; UNSPECIFIED SIDE EFFECT; WEAKNESS;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROGNOSIS; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 75149191500     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Damyanov C, Tzingilev B, Tabacov V. Treatment of orchiectomized patients with hormone-refractory prostate cancer with LH-RH agonists. Eur Urol 2001; 40: 474-477.
2. Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 2000; 105: 1045-1047.
3. Kerbe RS, Klement G, Pritchard KI, Kamen B. Continuous low-dose anti-angiogenic/metronomic chemotherapy: from the research laboratory into the oncology clinic. Ann Oncol 2002; 13: 12-15.
4. Bocci M, Tuccori U, Emmenegger V et al. Cyclophosphamide-methotrexate "metronomic" chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation. Ann Oncol 2005; 16: 1243-1252.
5. Young SD, Whissell M, Noble JC, Cano PO, Lopez PG, Germond CJ. Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and refecoxib in patients with advanced solid tumors. Clin Cancer Res 2006; 12: 3092-3098.
6. Ayre SG, Perez Garcia y Bellon D, Perez Garcia D Jr. Insulin potentiation therapy: a new concept for management of chronic degenerative diseases. Med Hypotheses 1986; 20: 199-210.
7. Ayre SG, Perez Garcia y Bellon D, Perez Garcia D Jr. Insulin, chemotherapy, and mechanisms of malignancy: the design and the demise of cancer. Med Hypotheses 2000; 55: 330-334.
8. Beretta G (Ed). Cancer treatment medical guide (10th edn). Farmitalia Carlo Erba-Erbamont, Milan, Italy, 1991.
9. Kasselman L, Kintner J, Sideris A et al. Dexamethasone treatment and ICAM-1 deficiency impair VEGF-induced angiogenesis in adult brain. J Vasc Res 2007; 44: 283-291.
10. Fontana A, Galli L, Fioravanti A et al. Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer. Clin Cancer Res 2009; 15: 4954.
11. Masferrer JL, Leahy KM, Koki AT et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2001; 60: 1306-1311.
12. Albertsson P, Lennernäs B, Norrby K. Chemotherapy and antiangiogenesis: drug-specific effects on microvessel sprouting. APMIS 2003; 111: 995-1003.
13. Saikali Z, Singh G. Doxycycline and other tetracyclines in the treatment of bone metastasis Anticancer Drugs 2003; 14: 773-778.
14. Yang SH, Lin JK, Chen WS, Chiu JH. Antiangiogenic effect of silymarin on colon cancer LoVo cell line. J Surg Res 2003; 113: 133-138.
15. Ayre SG, Perez Garcia y Bellon D, Perez Garcia D Jr. Neoadjuvant low-dose chemotherapy with insulin in breast carcinomas. Eur J Cancer 1990; 26: 1262-1263.
16. Lasalva-Prisco E, Cucchi S, Vasquez J, Lasalvia-Galante E, Golomar W, Gordon W. Insulin-induced enhancement of antitumoral response to methotrexate in breast cancer patients. Cancer Chemother Pharmacol 2004; 53: 204-220.
17. Hauser RA, Hauser RA (Eds). Treating cancer with insulin potentiation therapy. Beulah Land Press, Oak Park, Illinois, 2002.
18. Alabaster O, Vonderhaar BK, Shafie SM. Metabolic modification by insulin enhances methotrexate cytotoxicity in MCF-7 human breast cancer cells. Eur J Cancer Clin Oncol 1981; 17: 1223-1228.
19. Jiao SC, Huang J, Sun Y, Lu SX. The effect of insulin on chemotherapeutic drugs sensitivity in human esophageal and lung cancer cells. Zhonghua Yi Xue Za Zhi 2003; 83: 195-197.
20. Mountjoy KG, Holdaway IM, Finlay GJ. Insulin receptor regulation in cultured human tumor cells. Cancer Res 1983; 43: 4537-4542.
21. Schilisky R. Characteristics of membrane transport of methotrexate by cultured human breast cancer cells. Biochem Pharm 1981; 30: 1537-1542.
22. Zapf J. Insulin-like growth factors/somatomedins: structure, secretion, biological actions and physiological role. Hormone Res 1986; 24: 121-130.
23. Damyanov C, Tzingilev B, Tabacov V, Simeonov R. Initial experience of treatment of hormone-refractory prostate cancer with triptorelin acetate. J BUON 2001; 6: 341-342.